Deep Track Biotechnology Master Fund, Ltd. bought ATTO
August 6, 2026 · Form 4 insider transaction
Deep Track Biotechnology Master Fund, Ltd. bought 1,957,138 shares of Attovia Therapeutics, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.; Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.